
GRYPHON BIO
Diagnostic-Powered Therapeutics for Brain Health
OUR STORY
Gryphon Bio is an early-stage company created to harness our co-founders' discovery of unexpected waves of 1000s of brain molecules in the blood as novel therapeutic targets and temporal blood biomarkers (brain-specific proteins with blood levels that change over time like waves in the ocean). They made these discoveries over more than 20 years of “brain proteomic” research, the large-scale measurement of proteins in the brain.
Mission: To develop and market the first diagnostic-powered therapeutics for brain health.
Vision: To pioneer diagnostic-powered therapeutics to improve the lives of patients.
OUR PIPELINE
Diagnostic-Powered Therapeutics
We are researching a promising, diversified pipeline of large molecule medicines, known as biologics, by following clues from nature’s sequence of cellular and molecular events for CNS repair. Each biologic has a unique mechanism(s) of action (MOA) and pharmacokinetic/pharmacodynamic (PK/PD) profile, compelling biology, and binds to a novel or de-risked therapeutic target(s).
Development of these and other diagnostic-powered therapeutics will be performed by a wholly owned subsidiary of Gryphon Bio: Owl Therapeutics.
Brain Health
Virtual clinical trials, where blood specimens and cognitive assessments can be collected both in the hospital and at home or in the field, guide the development of our temporal CNS blood biomarkers and biologics. In the future, we envision close engagement with our patient communities to assess needs and to develop artificial intelligence-based telemedicine solutions for brain health.
Diagnostics
Novel blood tests based on temporal CNS blood biomarkers should improve the care, management, and hospitalization of our courageous patients. Potential indications of use should include screening for disease, predicting outcome, monitoring patients’ disease progression, and phenotyping individual trajectories to reconstruct and inform on key decisions (e.g., recovery, hospitalization, and return-to-work). Our novel blood tests should also improve the likelihood of regulatory approval of our biologics by health authorities.

OUR COURAGEOUS PATIENTS
CNS diseases are leading causes of death and disability, including:

Traumatic brain injury (TBI)
Alzheimer's disease (AD)
Neonatal Encephalopathy (NE)
Post-traumatic epilepsy (PTE)
Alexander's disease (AxD)
Alzheimer's disease related dementias (ADRD)
Multiple sclerosis (MS)
Brain metastatic breast cancer (bmBC)
Chronic traumatic encephalopathy (CTE)
Frontotemporal degeneration (FTD)
Spinal cord injury (SCI)
COVID-19
OUR INVESTORS
$13M
Non-Dilutive Funding (Grant Awards & Contracts)
$0.65M
Total Cash Raised
OUR COURAGEOUS TEAM
We are a proven, cohesive, interdisciplinary and internationally recognized team with deep experience in drug development (e.g., therapeutic bioconjugates), business development (e.g., licensing, intellectual property and partnerships) and CNS biomarker development (e.g., TBI). Together with our advisors, we have 1000+ previous peer-reviewed publications and $100M+ in previous grant awards. Moreover, we have successfully led several preclinical and clinical studies on successful high impact assets in industry and academe.
If you want to learn more about our amazing team members, get in touch.

OUR LATEST NEWS
What's New
Check our news section on a regular basis to always stay in the loop.